Table of Contents

    Topic review

    Extra-mammary Paget’s Disease

    View times: 9
    Submitted by: Angela Santoro

    Definition

    Extramammary Paget disease (EMPD) was first described by Crocker in 1889 in a man affected from bladder carcinoma and presented with an eczematous lesion involving the penoscrotal region, that was diagnosed as Paget disease in an extramammary site. Subsequently EMPD has been reported involving more frequently the external female genitalia and less commonly, the perianal/perineal region, groin, axilla, umbilicus, eyelids, and also external ear canal.

    EMPD has been defined by World Health Organization (WHO) as an intraepithelial neoplasm of epithelial origin expressing apocrine or eccrine glandular-like features and characterized by distinctive large cells with prominent cytoplasm, referred to as Paget cells’.

    1. Introduction

    The pathogenesis of EMPD is not fully understood; the stem cell compartment of the epidermis and hair follicle as well as Toker cells and mammary-like glands have been reported as possible sites of origin of Paget cells [6][7][8].

    Over time, different attempts to classify EMPD have been made and, in particular, at the vulvar site, a histopathological classification of VPD has been conceived, distinguishing primary/cutaneous VPD (type 1) from secondary/non-cutaneous VPD [9]. In detail, cutaneous VPD (type 1) is further subdivided according to the presence or absence of dermal invasion: type 1a (intraepithelial disease arising within the epidermis and extending into the epithelium of skin appendages and less commonly arising from the skin appendages and migrate to the overlying epidermis by epidermotropism); type 1b when focal invasion can be observed; type 1c when there is a cutaneous “pagetoid spread” from an underlying vulvar adenocarcinoma of the skin appendage or subcutaneous vulvar glands.

    The 5-year survival is highly variable, depending on the entity of infiltration, being, respectively, 100% and 88% for intraepithelial and micro-invasive disease (<1 mm), and only 15% when neoplastic invasion exceeds 1 mm [10].

    On the other hand, secondary VPD can originate by epidermotropic metastases or by direct extension from a malignancy of the gastrointestinal tract (type 2) or the uro-genital tract (type 3) [11][12].

    More recently, the WHO Classification of Tumours of Female Reproductive Organs (4th edition) considers to use the subdivision of cutaneous and non-cutaneous EMPD in routinary diagnosis [5].

    Given the rarity of EMPD, data on genetic alterations are largely unexplored. Findings regarding the hormonal status including Her2/Neu amplification are probably the most studied genetic alteration, likely because of their therapeutic potential but the clinical significance of these abnormalities still remains to be fully understood [13]. Being aware that at present the need of a tailored treatment for EMPD is a critical clinical goal, but its concrete availability is still too far to achieve, we reviewed the current literature in order to study the impact of IHC expression in VPD and EMPD in both genders of biological markers that could serve as potential prognostic/therapeutic factors, including human epidermal growth factor receptor 2 (HER2/neu), Estrogen Receptor (ER), Progesterone Receptor (PR), and Androgen Receptor (AR).

    2. Discussion

    EMPD, also referred as in situ adenocarcinoma of the skin, is a rare malignant disorder of skin occurring on cutaneous sites with abundant apocrine sweat glands and hair follicles [1][2][3][4][5]. The most common sites of occurrence are represented by the vulvar region, perineal, perianal, scrotal, and penile skin. Axilla, buttocks, thighs, eyelids, and the external auditory canal represent other uncommon sites of occurrence [1][2][3][4][5]. Clinically, EMPD manifests as erythematous or persistent, eczema-like skin lesions [1][2][3][4][5].

    The majority of primary EMPD, are confined to the epidermis, with a slow growth and exceptional metastases. However, cases with dermal invasion show an increased propensity for lymph node involvement and distant metastases [45]. In this subset of patients, imaging, ultrasound guided aspirative cytology, as well as sentinel lymph node biopsy have proven interesting results for the early detection of metastases and therapeutic management [46][47][48][49][50].

    Before rendering the diagnosis of primary Paget disease, synchronous or metachronous secondary malignancies arising from the underlying dermis and adjacent or distant organs must be taken into consideration. In detail, sweat gland adenocarcinoma, colorectal carcinoma, prostatic carcinoma, endometrioid adenocarcinoma, and urothelial carcinoma represent possible etiologic factors of secondary EMPD [6][9][11][12][51].

    In the present review and meta-analysis, we mainly focused on the hormonal environment and HER2 status in EMPD. Surprisingly, all papers before 2000 failed to demonstrate ER, PR, and AR expression, while, starting from 2000, we noted a hormonal background in EMPD mainly dominated by AR (Table 1). In detail, the observed expression rates for ER, PR, and AR were 13%, 9%, and 40%, respectively. Considering the patients’ sex, our results, in a total set of 4 studies involving 95 patients, have shown that the expression of ER was 12% (95% CI = 0.03–0.36) in female and 9% (95% CI= 0.00–0.68) in male patients and that the expression of PR was 9% (95% CI = 0.03–0.25) in female patients, and 2% in male patients. On the other hand, in a set of seven studies involving a total of 227 patients, higher expression rates of AR were detected both in female (40%; 95% CI = 0.34–0.47) and male (40%; 95% CI = 0.32–0.48) patients. According to these findings, anti-androgen target therapy seems promising tool in the management of EMPD [52].

    Table 1. Characteristics of Included Studies in the Meta-Analysis.

    Author Year Country Age
    (Mean or Median)
    Se
    X(% female)
    Total Cases Micro-Invasive/
    Invasive
    Cases
    (%)
    Positive
    Expression
    In Microinvasive/INVASIVE Cases (%)
    Marker Positive ihc Espression
    (%)
    Her2 Amplificatin Status (%)
    Aoyagi, et al. 2008 Japan 70.6 34.7 23 6/23
    (26)
    4/6 (66.6) HER2 F: 7/8 (87.5)
    M: 10/15 (66.6)
    N/A
    Bianco, et al. 2006 USA 75 100 15 N/A N/A HER2 6/15 (40) 1/15 (7)
    Brummer,
    et al.
    2004 Germany N/A 100 10 2/10
    (20)
    2/2
    100
    HER2 8/10 (80) N/A
    Diaz de Leon, et al. 2000 USA 64.5 82 28 N/A N/A AR
    PR
    ER
    F: 12/23 (52.2)
    M: 3/5 (60)
    0/28
    0/28
     
    Fujimoto, et al. 2000 Japan 67 26.6 30 13/30
    (43.3)
    9/13 (26.6) AR F: 8/8 (100)
    M: 16/22 (72.7)
     
    Garganese, et al. 2019 Italy 67 100 41 11/41
    (26.8)
    HER2
    4/11 (36.3)
    AR
    10/11 (90.9)
    PR
    2/11 (18)
    ER
    8/11 (72.7)
    HER2
    AR
    PR
    ER
    10/41 (24.4)
    33/41 (80.5)
    9/41 (22)
    29/41 (70.7)
    10/41 (24.4)
    Gatalica, et al. 2020 USA 61 72.2 18 15/18
    (83.3)
    AR 9/15(60)
    ER (4)/15 (26.6)
    AR
    ER
    F: 9/13 (69.2)
    M: 3/5 (60)
    F: 2/13 (15.3)
    M: 2/5 (40)
     
    Hanna, et al. 2003 Canada N/A 100 20 N/A N/A HER2 1/20 (5) 0/19
    Hikita, et al. 2012 Japan 70.47 64.70 17 23.5 ER 0/2
    PR 0/2
    HER2 8/8
    4/4(100)
    HER2 F: 9/11 (81.8)
    M: 3/6 (50)
    0/8
    Horn, et al. 2008 Germany N/A 100 8 N/A N/A HER2
    ER
    PR
    8/8 (100)
    1/8 (12.5)
    1/8 (12.5)
    N/A
    Inoguchi, et al. 2006 Japan 71.7 17.6 34 N/A N/A AR F: 1/6 (16.6)
    M: 14/23 (60.8)
     
    Kasashima, et al. 2010 Japan 71.5 44.8 58 16/58
    (27.5)
    9/16
    (56.2)
    AR F: 12/26 (46)
    M: 21/32 (65.6)
     
    Liegl, et al. 2005 Germany N/A 100 23 N/A N/A HER2
    AR
    PR
    ER
    12/23 (52)
    18/23 (78)
    0/23 (0)
    1/23 (4)
    N/A
    Liu, et al. 2009 USA 69 71.4 14 N/A N/A HER2 5/14 (35.7) N/A
    Lu, et al. 2018 China 63 0 11 N/A N/A HER2 3/11 (27.2) 2 (FISH+) + 1(genetic heterogeneity)/11
    Masuguchi, et al. 2011 Japan N/A 41.9 31 11/31
    (35.4)
    10/11
    (90.9)
    HER-2 F: 7/13 (53.8)
    M: 12/18 (66.6)
    N/A
    Miyamoto, et al. 2010 Japan 74 43.7 32 19/32
    (59.3)
    13/19
    (68)
    HER2 F: 7/14 (50)
    M: 13/18 (72)
    2/5 (40)
    Morbeck, et al. 2016 Brazil 66.8 100 11 2/11
    (18)
    2/2
    (100)
    HER2 6/11 (54.5) 2/6
    (33.3)
    Ogawa, et al. 2005 Japan 68.5 14.7 34 16/34
    (47)
    18/34
    (52.9)
    5/18 (27.7) HER2 F: 1/5 (20)
    M: 6/29 (20.6)
    3/7
    (42.8)
    Plaza, et al. 2009 USA 66 70.2 47 2/47
    (4.2)
    0/2
    (0)
    HER2 F: 14/33 (42.4)
    M: 1/14 (7)
    N/A
    Reich, et al. 2005 Austria 63 100 6 N/A N/A HER2 4/6 (66.6) 4/6 (66.6)
    Richter, et al. 2010 USA 68.5 100 33/39 * 7/33
    (21)
    5/7
    (71)
    HER2 19/33
    (57.5)
    N/A
    Sekiguchi, et al. 2020 Japan 71 50 4 N/A N/A HER2 F: 2/2 (100)
    M: 2/2 (100)
    2 amplified
    2 polysomic
    Tanaka, et al. 2016 Japan 72 15.3 26 26/26
    (100)
    6/26
    (23.07)
    HER2 F: 2/4 (50%)
    M: 4/22 (18)
    5/6
    (83.3)
    Tanaka, et al. 2013 Japan 71.1 33.6 104 73/104
    (36.5)
    10/73
    (13.7)
    HER2 F: 5/35 (14.2)
    M: 7/69 (10)
    12/16
    (75)
    Tanskanen, et al. 2003 Finland 65.47 60.8 23 3/23
    (13.04)
    1/3
    (33.3)
    HER2 F: 12/23 (52)
    M: 4/9 (44.44)
    10/23
    (43.47)
    Zhang, et al. 2015 China 61.5 0 2 1/2
    (50)
    1/2
    (50)
    HER2 1/2 (50) N/A
    * Tissue specimens available for Her-2/neu testing.

    Regarding ER and PR expression in EMPD, limited and conflicting results are still available. However, a recent study by Garganese et al., reported a remarkably high percentage of ER-positive EMPD (at least 70%), which may provide novel insights in the future hormonal treatment of this disease [19].

    Regarding HER2 status, our results indicated that, in a highly heterogeneous set of 27 studies, the overall rate of HER2/neu expression was 30% (95% CI = 0.25–0.36; Q = 34.47; I2 = 39.08). Considering the patients’ sex, the performed analyses have also indicated that the expression of HER2/neu in female and male patients was 32% (95% CI = 0.27–0.38) and 26% (95% CI=0.18–0.36), respectively. Moreover, some authors highlighted a possible correlation between HER2 overexpression and disease recurrence, dermal invasion, and lymph-node metastases [33][34][35][36].

    Few studies have also analyzed HER2 overexpression and gene amplification in metastatic patients. Ogawa et al. have found HER2 overexpression in 19.4% of the lesions, three of which with HER2 amplification by CISH [32]. Tanaka et al. reported that the ERBB2 gene was amplified in all cases with a HER2 score of 3+ [37]. Other authors detected by CISH HER2 gene amplification in 43% of the lesions. HER2 protein overexpression (score 3+ by IHC) was found in 12 tumors (52%), including all 10 tumors with gene amplification [39].

    A good overall concordance between HER2 status in primary tumors and in the corresponding metastatic sites has also been described in EMPD [37]. This finding contrasts with the reported discordance rates of HER2 expression between primary and metastatic lesions reported for breast and gastric cancer [53].

    According to these results, we can conclude that HER2/neu overexpression is found in at least one-third of EMPD lesions, probably characterized by poor outcome related to deep invasion, recurrence, and node metastases. However, therapies targeting HER2 may be useful in treating HER2 positive advanced and/or metastatic patients [28][36].

    Moreover, several studies in the field of epigenetics have documented the pathogenic role of MicroRNAs (miRNAs) in different solid tumors, including HER2 positive breast cancer [54][55][56]. MiRNAs are small endogenous non-coding RNAs with a wide range of cellular functions. In breast cancer, both oncogenic and tumor suppressor properties have been related to specific miRNAs. In detail, miRNAs are involved in different stages of breast cancer progression, such as tumor growth, apoptosis, differentiation, angiogenesis, metastasis, and drug resistance [54][55][56]. Importantly, the tumor suppressor role of miRNAs has been recently highlighted also in HER2-overexpressing breast cancer where they mediate the downstream signaling of HER2, suppress the expression of HER2 and affect responses to anti-HER2 therapies [55].

    In this regard, understanding the role of miRNAs in HER2-positive tumors is of great importance for the future development of novel and individualized target-therapies.

    The entry is from 10.3390/diagnostics10121040

    References

    1. Crocker, H.R. Paget’s disease affecting the scrotum and penis. Trans. Pathol. Soc. Lond. 1889, 40, 187–191. [Google Scholar]
    2. Crawford, D.; Nimmo, M.; Clement, P.B.; Thomson, T.; Benedet, J.L.; Miller, D.; Gilks, C.B. Prognostic factors in Paget’s disease of the vulva: A study of 21 cases. Int. J. Gynecol. Pathol. 1999, 18, 351–359. [Google Scholar] [CrossRef] [PubMed]
    3. Chen, Y.H.; Wong, T.W.; Lee, J.Y. Depigmented genital extramammary Paget’s disease: A possible histogenetic link to Toker’s clear cells and clear cell papulosis. J. Cutan Pathol. 2001, 28, 105–108. [Google Scholar] [CrossRef] [PubMed]
    4. Zollo, J.D.; Zeitouni, N.C. The Roswell Park Cancer Institute experience with extramammary Paget’s disease. Br. J. Dermatol. 2000, 142, 59–65. [Google Scholar] [CrossRef]
    5. Crum, C.P.; Herrington, C.S.; McCluggage, W.G.; Regauer, S.; Wilkinson, E.J. Tumours of the vulva. In WHO Classification of Tumours of Female Reproductive Organs, 4th ed.; Kurman, R.J., Carcangiu, M.L., Herrington, C.S., Young, R.H., Eds.; International Agency for Research on Cancer: Lyon, France, 2014; pp. 236–237. [Google Scholar]
    6. Mehta, N.J.; Torno, R.; Sorra, T. Extramammary Paget’s disease. South Med. J. 2000, 93, 713–715. [Google Scholar] [CrossRef]
    7. Willman, J.H.; Golitz, L.E.; Fitzpatrick, J.E. Vulvar clear cells of Toker: Precursors of extramammary Paget’s disease. Am. J. Dermatopathol. 2005, 27, 185–188. [Google Scholar] [CrossRef]
    8. Van der Putte, S.C. Mammary-like glands of the vulva and their disorders. Int. J. Gynecol. Pathol. 1994, 13, 150–160. [Google Scholar] [CrossRef]
    9. Wilkinson, E.J.; Brown, H.M. Vulvar Paget disease of urothelial origin: A report of three cases and a proposed classification of vulvar Paget disease. Hum. Pathol. 2002, 33, 549–554. [Google Scholar] [CrossRef]
    10. Van der Linden, M.; Meeuwis, K.A.; Bulten, J.; Bosse, T.; van Poelgeest, M.I.; de Hullu, J.A. Paget disease of the vulva. Crit. Rev. Oncol. Hematol. 2016, 101, 60–74. [Google Scholar] [CrossRef]
    11. Nowak, M.A.; Guerriere-Kovach, P.; Pathan, A.; Campbell, T.E.; Deppisch, L.M. Perianal Paget’s disease: Distinguishing primary and secondary lesions using immunohistochemical studies including gross cystic disease fluid protein-15 and cytokeratin 20 expression. Arch. Pathol. Lab. Med. 1998, 122, 1077–1081. [Google Scholar]
    12. Phyo, A.K.; Mun, K.S.; Kwan, K.C.; Ann, C.C.; Kuppusamy, S. Genitourinary extramammary Paget’s disease: Review and outcome in a multidisciplinary setting. Int. J. Clin. Exp. Pathol. 2020, 13, 2369–2376. [Google Scholar] [PubMed]
    13. Mantovani, G.; Fagotti, A.; Franchi, M.; Scambia, G.; Garganese, G. Reviewing vulvar Paget’s disease molecular bases. Looking forward to personalized target therapies: A matter of CHANGE. Int. J. Gynecol. Cancer 2019, 29. [Google Scholar] [CrossRef] [PubMed]
    14. Aoyagi, S.; Akiyama, M.; Shimizu, H. High expression of Ki-67 and cyclin D1 in invasive extramammary Paget’s disease. J. Dermatol. Sci. 2008, 50, 177–184. [Google Scholar] [CrossRef] [PubMed]
    15. Bianco, M.K.; Vasef, M.A. HER-2 Gene Amplification in Paget Disease of the Nipple and Extramammary Site: A Chromogenic In Situ Hybridization Study. Diagn. Mol. Pathol. 2006, 15, 131–135. [Google Scholar] [CrossRef]
    16. Brummer, O.; Stegnerb, H.E.; Bfhmera, G.; Kqhnlea, H.; Petry, K.U. HER-2/neu expression in Paget disease of the vulva and the female breast. Ginecol. Oncol. 2004, 95, 336–340. [Google Scholar] [CrossRef]
    17. Diaz de Leon, E.; Carcangiu, M.L.; Prieto, V.G.; McCue, P.A.; Burchette, J.L.; To, G.; Norris, B.A.; Kovatich, A.J.; Sanchez, R.L.; Krigman, H.R.; et al. Extramammary Paget Disease Is Characterized by the Consistent Lack of Estrogen and Progesterone Receptors But Frequently Expresses Androgen Receptor. Am. J. Clin. Pathol. 2000, 113, 572–575. [Google Scholar] [CrossRef]
    18. Fujimoto, A.; Takata, M.; Hatta, N.; Takehara, K. Expression of Structurally Unaltered Androgen Receptor in Extramammary Paget’s Disease. Lab. Investig. 2000, 80, 1465–1471. [Google Scholar] [CrossRef]
    19. Garganese, G.; Inzani, F.; Mantovani, G.; Santoro, A.; Valente, M.; Babini, G.; Petruzzellis, G.; Fragomeni, S.M.; Gentileschi, S.; Bove, S.; et al. The vulvar immunohistochemical panel (VIP) project: Molecular profiles of vulvar Paget’s disease. J. Cancer Res. Clin. Oncol. 2019, 145, 2211–2225. [Google Scholar] [CrossRef]
    20. Gatalica, Z.; Vranic, S.; Krušlin, B.; Poorman, K.; Stafford, P.; Kacerovska, D.; Senarathne, W.; Florento, E.; Contreras, E.; Leary, A.; et al. Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget’s disease. Cancer Med. 2020, 9, 1441–1450. [Google Scholar] [CrossRef]
    21. Hanna, W.; Alowami, S.; Malik, A. The role of HER-2/neu oncogene and vimentin filaments in the production of the Paget’s phenotype. Breast J. 2003, 9, 485–490. [Google Scholar] [CrossRef]
    22. Hikita, T.; Ohtsuki, Y.; Maeda, T.; Furihata, M. Immunohistochemical and fluorescence in situ hybridization studies on noninvasive and invasive extramammary Paget’s disease. Int. J. Surg. Pathol. 2012, 20, 441–448. [Google Scholar] [CrossRef] [PubMed]
    23. Horn, L.C.; Purz, S.; Krumpe, C.; Bilek, K. COX-2 and Her-2/neu are overexpressed in Paget’s disease of the vulva and the breast: Results of a preliminary study. Arch. Gynecol. Obstet. 2008, 277, 135–138. [Google Scholar] [CrossRef] [PubMed]
    24. Inoguchi, N.; Matsumura, Y.; Kanazawa, N.; Morita, K.; Tachibana, T.; Sakurai, T.; Utani, A.; Miyachi, Y. Expression of prostate-specific antigen and androgen receptor in extramammary Paget’s disease and carcinoma. Clin. Exp. Dermatol. 2007, 32, 91–94. [Google Scholar] [CrossRef] [PubMed]
    25. Kasashima, S.; Ozaki, S.; Kawashima, A.; Zen, Y.; Moriya, T.; Inoue, M. Androgen receptor and 5alphareductase immunohistochemical profiles in extramammary Paget disease. Br. J. Dermatol. 2010, 162, 1098–1102. [Google Scholar] [CrossRef] [PubMed]
    26. Liegl, B.; Horn, L.C.; Moinfar, F. Androgen receptors are frequently expressed in mammary and extramammary Paget’s disease. Mod. Pathol. 2005, 18, 1283–1288. [Google Scholar] [CrossRef]
    27. Liu, W.; Iqbal, J.; Khoury, T. Mammary Paget’s disease and extra-mammary Paget’s disease: Two morphologically similar but biologically different diseases. J. Cutan Pathol. 2010, 37, 1145–1149. [Google Scholar] [CrossRef]
    28. Lu, X.; Zhang, P.; Zhu, Y.; Ye, D. Human epidermal growth factor receptor 2 amplification as a biomarker for treatment in patients with lymph node-metastatic penoscrotal extramammary Paget’s disease. Oncol. Lett. 2019, 17, 2677–2686. [Google Scholar] [CrossRef]
    29. Masuguchi, S.; Jinnin, M.; Fukushima, S.; Makino, T.; Sakai, K.; Inoue, Y.; Igata, T.; Ihn, H. The expression of HER-2 in extramammary Paget’s disease. BioScience Trends 2011, 5, 151–155. [Google Scholar] [CrossRef]
    30. Miyamoto, A.; Akasaka, K.; Oikawa, H.; Akasaka, T.; Masuda, T.; Maesawa, C. Immunohistochemical study of HER2 and TUBB3 proteins in extramammary Paget disease. Am. J. Dermatopathol. 2010, 32, 578–585. [Google Scholar] [CrossRef]
    31. Morbeck, D.; Tregnago, A.C.; Netto, G.B.; Sacomani, C.; Peresi, P.M.; Osório, C.T.; Schutz, L.; Bezerra, S.M.; de Brot, L.; Cunha, I.W. GATA3 expression in primary vulvar Paget disease: A potential pitfall leading to misdiagnosis of pagetoid urothelial intraepithelial neoplasia. Histopathology 2017, 70, 435–441. [Google Scholar] [CrossRef]
    32. Ogawa, T.; Nagashima, Y.; Wada, H.; Akimoto, K.; Chiba, Y.; Nagatani, T.; Inayama, Y.; Yao, M.; Aoki, I.; Ikezawa, Z. Extramammary Paget’s disease: Analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein. Hum. Pathol. 2005, 36, 1273–1280. [Google Scholar] [CrossRef] [PubMed]
    33. Plaza, J.A.; Torres-Cabala, C.; Ivan, D.; Prieto, V.G. HER-2/neu expression in extramammary Paget disease:a clinicopathologic and immunohistochemistry study of 47 cases with and without underlying malignancy. J. Cutan Pathol. 2009, 36, 729–733. [Google Scholar] [CrossRef] [PubMed]
    34. Reich, O.; Liegl, B.; Tamussino, K.; Regauer, S. p185HER2 overexpression and HER2 oncogene amplification in recurrent vulvar Paget’s disease. Mod. Pathol. 2005, 18, 354–357. [Google Scholar] [CrossRef] [PubMed]
    35. Richter, C.E.; Hui, P.; Buza, N.; Silasi, D.A.; Azodi, M.; Santin, A.D.; Schwart, P.E.; Rutherford, T.J. HER-2/NEU overexpression in vulvar Paget disease: The Yale experience. J. Clin. Pathol. 2010, 63, 544–573. [Google Scholar] [CrossRef]
    36. Sekiguchi, N.; Kubota, S.; Noguchi, T.; Fukushima, T.; Kobayashi, T.; Kanda, S.; Koizumi, T.; Miyake, T.; Shirai, T.; Okuyama, R. Experiences of trastuzumab plus paclitaxel combination therapy in metastatic human epidermal growth factor receptor 2-positive extramammary Paget’s disease: Four cases and a review. J. Dermatol. 2020, 47, 1276–1279. [Google Scholar] [CrossRef]
    37. Tanaka, R.; Sasajima, Y.; Tsuda, H.; Namikawa, K.; Takahashi, A.; Tsutsumida, A.; Fujimoto, M.; Yamazaki, N. Concordance of the HER2 protein and gene status between primary and corresponding lymph node metastatic sites of extramammary Paget disease. Clin. Exp. Metastasis 2016, 33, 687–697. [Google Scholar] [CrossRef]
    38. Tanaka, R.; Sasajima, Y.; Tsuda, H.; Namikawa, K.; Tsutsumida, A.; Otsuka, F.; Yamazaki, N. Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease. Br. J. Dermatol. 2013, 168, 1259–1266. [Google Scholar] [CrossRef]
    39. Tanskanen, M.; Jahkola, T.; Asko-Seljavaara, S.; Jalkanen, J.; Isola, J. HER2 oncogene amplification in extramammary Paget’s disease. Histopathology 2003, 42, 575–579. [Google Scholar] [CrossRef]
    40. Zhang, X.; Jin, W.; Zhu, H.; Yu, H. Extramammary Paget’s Disease in Two Brothers. Indian J. Dermatol. 2015, 60, 423. [Google Scholar]
    41. Huedo-Medina, T.B.; Sanchez-Meca, J.; Marìn-Martìnez, F.; Botella, J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol. Methods 2006, 11, 193–206. [Google Scholar] [CrossRef]
    42. Higgins, J.P.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327, 557–560. [Google Scholar] [CrossRef] [PubMed]
    43. Egger, M.; Davey Smith, G.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315, 629–634. [Google Scholar] [CrossRef] [PubMed]
    44. Begg, C.B.; Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50, 1088–1101. [Google Scholar] [CrossRef] [PubMed]
    45. Shiomi, T.; Noguchi, T.; Nakayama, H.; Yoshida, Y.; Yamamoto, O.; Hayashi, N.; Ohara, K. Clinicopathological study of invasive extramammary Paget’s disease: Subgroup comparison according to invasion depth. J. Eur. Acad. Dermatol. Venereol. 2013, 27, 589–592. [Google Scholar] [CrossRef] [PubMed]
    46. Fujisawa, Y.; Yoshino, K.; Kiyohara, Y.; Kadono, T.; Murata, Y.; Uhara, H.; Hatta, N.; Uchi, H.; Matsushita, S.; Takenouchi, T.; et al. The role of sentinel lymph node biopsy in the management of invasive extramammary Paget’s disease: Multi-center, retrospective study of 151 patients. J. Dermatol. Sci. 2015, 79, 38–42. [Google Scholar] [CrossRef] [PubMed]
    47. Angelico, G.; Santoro, A.; Inzani, F.; Spadola, S.; Fiorentino, V.; Cianfrini, F.; Carbone, C.; Garganese, G.; Rossi, E.D.; Scambia, G.; et al. Ultrasound-guided FNA cytology of groin lymph nodes improves the management of squamous cell carcinoma of the vulva: Results from a comparative cytohistological study. Cancer Cytopathol. 2019, 127, 514–520. [Google Scholar] [CrossRef]
    48. Garganese, G.; Fragomeni, S.M.; Pasciuto, T.; Leombroni, M.; Moro, F.; Evangelista, M.T.; Bove, S.; Gentileschi, S.; Tagliaferri, L.; Paris, I.; et al. Ultrasound morphometric and cytologic preoperative assessment of inguinal lymph-node status in women with vulvar cancer: MorphoNode study. Ultrasound Obstet Gynecol. 2020, 55, 401–410. [Google Scholar] [CrossRef]
    49. Garganese, G.; Collarino, A.; Fragomeni, S.M.; Rufini, V.; Perotti, G.; Gentileschi, S.; Evangelista, M.T.; Ieria, F.P.; Zagaria, L.; Bove, S.; et al. Groin sentinel node biopsy and 18F-FDG PET/ CT-supported preoperative lymph node assessment in cN0 patients with vulvar cancer currently unfit for minimally invasive inguinal surgery: The GroSNaPET study. Eur. J. Surg. Oncol. 2017, 43, 1776–1783. [Google Scholar] [CrossRef]
    50. Collarino, A.; Fuoco, V.; Garganese, G.; Pereira Arias-Bouda, L.M.; Perotti, G.; Manca, G.; Vidal-Sicart, S.; Giammarile, F.; de Geus-Oei, L.F.; Scambia, G.; et al. Lymphoscintigraphy and sentinel lymph node biopsy in vulvar carcinoma: Update from a European expert panel. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 1261–1274. [Google Scholar] [CrossRef]
    51. Inzani, F.; Angelico, G.; Santoro, A.; Musarra, T.; Valente, M.; Spadola, S.; Garganese, G.; Fragomeni, S.; Scambia, G.; Zannoni, G.F. A new entity in the pathological spectrum of vulvar neoplasms: The first report of a primary endometrioid adenocarcinoma. Int. J. Gynaecol. Obstet. 2019, 147, 270–272. [Google Scholar] [CrossRef]
    52. Yoneyama, K.; Kamada, N.; Kinoshita, K.; Kawashima, T.; Otani, M.; Endo, H.; Shinkai, H.; Utani, A. Androgen-deprivation regimen for multiple bone metastases of extramammary Paget disease. Br. J. Dermatol. 2005, 153, 853–855. [Google Scholar] [CrossRef] [PubMed]
    53. Ieni, A.; Angelico, G.; Giuffrè, G.; Tuccari, G. Discordance Rate of HER2 Status in Primary Gastric Cancer and Synchronous Lymph Node Metastases: Its Impact on Therapeutic Decision and Clinical Management. Pathol. Oncol. Res. 2018, 24, 695–696. [Google Scholar] [CrossRef] [PubMed]
    54. Leone, P.; Buonavoglia, A.; Fasano, R.; Solimando, A.G.; De Re, V.; Cicco, S.; Vacca, A.; Racanelli, V. Insights into the Regulation of Tumor Angiogenesis by Micro-RNAs. J. Clin. Med. 2019, 8, 2030. [Google Scholar] [CrossRef] [PubMed]
    55. Wang, S.E.; Lin, R.J. MicroRNA and HER2-overexpressing cancer. Microrna 2013, 2, 137–147. [Google Scholar] [CrossRef] [PubMed]
    56. Goradel, N.H.; Mohammadi, N.; Haghi-Aminjan, H.; Farhood, B.; Negahdari, B.; Sahebkar, A. Regulation of tumor angiogenesis by microRNAs: State of the art. J. Cell Physiol. 2019, 234, 1099–1110.
    More